TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17399635

Group type: EXPERIMENTAL
Intervention: Corticosteroids (intermediate doses of 50-210 mg dexamethasone equivalent)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Corticosteroids (lower doses up to 8 mg)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Corticosteroids (higher doses 236-2850 mg)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990
Study: 16338449

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7599
Study: 12643410

Group type: EXPERIMENTAL
Intervention: Warm cardioplegia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tepid blood cardioplegia
Number of subjects: 70
Study: 9652859

Group type: EXPERIMENTAL
Intervention: Radiation Oncologists (RO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Radiologists
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 11
Study: 9604043

Group type: EXPERIMENTAL
Intervention: Shorter time frame (48 hours)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard time frame (2 weeks)
Number of subjects: 200
Study: 2008948

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4-5.0 mg.kg-1
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg.kg-1
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Midazolam 1.0 mg.kg-1 or greater
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Midazolam 2.0 mg.kg-1 or greater
Number of subjects: 67
Study: 6800869

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (low-dose, 375 mg/day)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (high-dose, 750 mg/day)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: High-dose chenodeoxycholic acid
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: High-dose chenodeoxycholic acid (women)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo (women)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid therapy
Number of subjects: 763
Study: 31088090

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DXM) 0.5 mcg/kg with 0.5% ropivacaine 20 mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone (DXA) 8 mg with 0.5% ropivacaine 20 mL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DXM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dexamethasone (DXA)
Number of subjects: 60
Study: 29295513

Group type: EXPERIMENTAL
Intervention: 10 µg/day vitD3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 µg/day 25OH‐D3
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 µg/day vitD2
Number of subjects: 12
Study: 25407846

Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wheat germs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Camembert cheese
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pteroylmonoglutamic acid
Number of subjects: 24
Study: 27863273

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (2min post-delivery)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Early cord clamping (ECC) (<10s post-delivery)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 97
Study: 22658512

Group type: EXPERIMENTAL
Intervention: Early salvage hormonal therapy (PSA≤10 ng/mL and absent distant metastases)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Late salvage hormonal therapy (PSA>10 ng/mL and absent distant metastases)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Late salvage hormonal therapy (distant metastases)
Number of subjects: 102
Study: 21613439

Group type: EXPERIMENTAL
Intervention: Percutaneous disk decompression (PDD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conservative therapy
Number of subjects: 31
Study: 19028742

Group type: EXPERIMENTAL
Intervention: Wide-field digital retinal imaging (WFDRI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Binocular indirect ophthalmoscopy (BIO)
Number of subjects: 81
Study: 16448282

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + primer + composite + conventional Victory bracket
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid + primer + precoated Victory bracket
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SEP + composite + conventional bracket
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SEP + precoated bracket
Number of subjects: 23
Study: 14985515

Group type: EXPERIMENTAL
Intervention: Congested streets
Number of subjects: 448

Group type: COMPARATOR
Intervention: Uncongested streets
Number of subjects: 448
Study: 11737404

Group type: COMPARATOR
Intervention: Standard trial information (SI) alone (n = 27)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standard trial information (SI) plus a 16 page information booklet (n = 23)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (SI and SI plus booklet)
Number of subjects: 50
Study: 9914274

Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex during voluntary ankle dorsiflexion (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex during stance phase of walking (soleus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex during stance phase of walking (inactive TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal transcranial magnetic stimulation of the motor cortex at various phases of the step cycle
Number of subjects: 0
Study: 8084974

Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2666080

Group type: EXPERIMENTAL
Intervention: Effervescent tablets A (161 mg daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Effervescent tablets A* (161 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Proprietary iron preparation B (150 mg daily)
Number of subjects: 24
Study: 909253

Group type: EXPERIMENTAL
Intervention: Euthyscope followed by occlusion
Number of subjects: 63

Group type: COMPARATOR
Intervention: Occlusion
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Euthyscope treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison of amblyopes with anisometropic and microstrabismic patients
Number of subjects: 63

Group type: COMPARATOR
Intervention: Refraction in amblyopic eyes
Number of subjects: 63
Study: 31906948

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ex vivo susceptibility to monodesethylamodiaquine
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Lumefantrine and monodesethylamodiaquine
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 440
Study: 31264138

Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glargine U100
Number of subjects: 0
Study: 28793772

Group type: EXPERIMENTAL
Intervention: HSFA diet, rich in saturated fat
Number of subjects: 75

Group type: COMPARATOR
Intervention: HMUFA diet, rich in monounsaturated fat
Number of subjects: 75

Group type: COMPARATOR
Intervention: LFHCC n‐3 diet, low-fat, rich in complex carbohydrate supplemented with n‐3 polyunsaturated fatty acids
Number of subjects: 75

Group type: COMPARATOR
Intervention: LFHCC low-fat diet, rich in complex carbohydrate supplemented with placebo
Number of subjects: 75
Study: 25294839

Group type: EXPERIMENTAL
Intervention: Vertical vibration (VV)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Side-alternating vibration (SV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 61
Study: 23518443

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 40% Salicylic acid self-application
Number of subjects: 250

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 250
Study: 21636861

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m(2) weekly for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Historical controls (no rituximab)
Number of subjects: 40
Study: 18834692

Group type: EXPERIMENTAL
Intervention: RCT participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment seekers
Number of subjects: 0
Study: 16247584

Group type: COMPARATOR
Intervention: Biodex Stability System at level 8
Number of subjects: 74

Group type: COMPARATOR
Intervention: Biodex Stability System at level 2
Number of subjects: 74
Study: 14993771

Group type: EXPERIMENTAL
Intervention: Nicorandil (4 mg iv and 4 mg ic before reperfusion, followed by continuous infusion at 4 mg/h for 24 h)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Magnesium (10 mmol iv before reperfusion, followed by continuous infusion at 0.4 mmol/h for 24 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study: 11782040

Group type: EXPERIMENTAL
Intervention: Refined estimator for the variance of the treatment effect estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed test for overall treatment effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of controlled multi-centre study with binary outcome
Number of subjects: 0
Study: 9293679

Group type: EXPERIMENTAL
Intervention: 10% sucralfate in sorbolene cream
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sorbolene alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 39
Study: 9300326

Group type: EXPERIMENTAL
Intervention: SNX‐111 (neuron-specific, N-type, voltage-sensitive calcium channel blocker)
Number of subjects: 0
Study: 2527274

Group type: EXPERIMENTAL
Intervention: rHBV vaccine (2 micrograms)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: rHBV vaccine (5 micrograms)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: rHBV vaccine (10 micrograms)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: rHBV vaccine (20 micrograms)
Number of subjects: 482

Group type: COMPARATOR
Intervention: plasma-derived hepatitis B virus vaccine (Hevac B Pasteur)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: rHBV vaccine (10 and 20 micrograms)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: rHBV vaccine
Number of subjects: 482
Study: 1106927

Group type: EXPERIMENTAL
Intervention: Transfer factor therapy (equivalent to 2‐1 X 10(8) leucocytes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 30803309

Group type: EXPERIMENTAL
Intervention: Ving Tsun (VT) training, 2 sessions per week for 3 months (24 sessions)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 27989407

Group type: EXPERIMENTAL
Intervention: Family-based intervention including 6 nurse-led individual face-to-face and telephone counseling sessions within 1 month and a voluntary face-to-face family counseling session (FCS)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Family-based intervention including FCS
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Control group received a leaflet, a self-help booklet, and brief quitting advice only
Number of subjects: 1158
Study: 26598475

Group type: EXPERIMENTAL
Intervention: Risperidone (RISP)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Lithium carbonate (LI)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Divalproex sodium (VAL)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: All treatment groups (RISP, LI, VAL)
Number of subjects: 279
Study: 23463179

Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme Self‐help (NFPP‐SH)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 43
Study: 22112960

Group type: EXPERIMENTAL
Intervention: Management by a specialist multidisciplinary team for six weeks according to a care plan agreed between the professionals and the patient and carer (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team management and additional support for four months from a trained care assistant (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care, no coordinated team care planning or ongoing support (Group C)
Number of subjects: 0
Study: 19697823

Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 50

Group type: COMPARATOR
Intervention: COBRA-PLA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 50
Study: 16469987

Group type: COMPARATOR
Intervention: Apples fortified with deuterium-labeled alpha-tocopheryl acetate at 0% fat
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Apples fortified with deuterium-labeled alpha-tocopheryl acetate at 6% fat
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Apples fortified with deuterium-labeled alpha-tocopheryl acetate at 21% fat
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 5
Study: 15282428

Group type: EXPERIMENTAL
Intervention: ACIST Injection System (automated contrast injection)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Manual injection (control group)
Number of subjects: 453
Study: 11302274

Group type: EXPERIMENTAL
Intervention: Applied Family Management (AFM) including 1 year of behavioral family therapy plus support groups for 2 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive Family Management (SFM) including monthly support groups for 2 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard, low, targeted neuroleptic dosage strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-limited behavioral family therapy added to monthly support groups
Number of subjects: 0
Study: 9531235

Group type: EXPERIMENTAL
Intervention: Hospital-based smoking intervention consisting of a 15-minute bedside counseling session, written self-help material, a chart prompt for physicians, and up to 3 weekly counseling telephone calls after discharge.
Number of subjects: 650

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Hospital-based smoking intervention.
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Hospital-based smoking intervention among patients who had not previously tried to quit smoking.
Number of subjects: 650

Group type: COMPARATOR
Intervention: Usual care (control group) among patients who had not previously tried to quit smoking.
Number of subjects: 650
Study: 8103527

Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (n = 15)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sodium nitroprusside (n = 18)
Number of subjects: 33
Study: 3513596

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing zinc polycarboxylate cement
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing glass ionomer cement
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard orthodontic cement zinc phosphate
Number of subjects: 180
Study: 29735284

Group type: EXPERIMENTAL
Intervention: Music listening intervention (60 minutes, twice a day, over three days)
Number of subjects: 40
Study: 27479951

Group type: EXPERIMENTAL
Intervention: Telestroke intervention
Number of subjects: 2657
Study: 24344111

Group type: EXPERIMENTAL
Intervention: 7% Hypertonic saline with epinephrine
Number of subjects: 101

Group type: COMPARATOR
Intervention: 0.9% saline with epinephrine (Control)
Number of subjects: 101
Study: 22075478

Group type: EXPERIMENTAL
Intervention: autotitrating continuous positive airway pressure (autoCPAP) in autotitrating mode
Number of subjects: 34

Group type: COMPARATOR
Intervention: fixed subtherapeutic pressure (detection assessment)
Number of subjects: 34
Study: 19892350

Group type: EXPERIMENTAL
Intervention: Astaxanthin 6 mg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Astaxanthin 12 mg/day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Astaxanthin 18 mg/day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 18033318

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 209

Group type: COMPARATOR
Intervention: HLA-matched sibling transplantation
Number of subjects: 209
Study: 15988245

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 36
Study: 12464836

Group type: EXPERIMENTAL
Intervention: Topical aloe vera gel
Number of subjects: 225

Group type: COMPARATOR
Intervention: Topical aqueous cream
Number of subjects: 225
Study: 10499484

Group type: EXPERIMENTAL
Intervention: Cholylsarcosine 6 g/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cholylsarcosine 12 g/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cholylsarcosine
Number of subjects: 4
Study: 7565257

Group type: EXPERIMENTAL
Intervention: Gastric emptying plus activated charcoal (E group)
Number of subjects: 876

Group type: COMPARATOR
Intervention: Activated charcoal alone (NE group)
Number of subjects: 876
Study: 1941185

Group type: EXPERIMENTAL
Intervention: Leavened whole-wheat bread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leavened whole-wheat bread with milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extruded cereal from intrinsically labeled wheat bran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extruded cereal with milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leavened bread
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cookies (underbaked and overbaked)
Number of subjects: 0
Study: 6379529

Group type: EXPERIMENTAL
Intervention: Fetal biophysical profile scoring
Number of subjects: 735

Group type: COMPARATOR
Intervention: Nonstress testing
Number of subjects: 735
Study: 29504440

Group type: EXPERIMENTAL
Intervention: Community-based exercise program (n = 133)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Control group (n = 129)
Number of subjects: 262
Study: 31487290

Group type: EXPERIMENTAL
Intervention: Increased language ability
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Poor language ability (bottom 10% of sample)
Number of subjects: 200
Study: 28542080

Group type: EXPERIMENTAL
Intervention: Point-of-Care Testing (POCT)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 432
Study: 27668927

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Activities of daily living (Katz ADL)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Severity of dementia
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Psychiatric disorders
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Pulmonary diseases
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 288
Study: 25118999

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 33
Study: 22236534

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 284

Group type: COMPARATOR
Intervention: Percutaneous cholecystostomy
Number of subjects: 284
Study: 19108877

Group type: COMPARATOR
Intervention: Cisplatin (50 mg/m(2)) and Doxorubicin (45 mg/m(2))
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m(2)), Doxorubicin (45 mg/m(2)), and Paclitaxel (160 mg/m(2))
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Cisplatin, Doxorubicin, and Paclitaxel
Number of subjects: 552

Group type: COMPARATOR
Intervention: Cisplatin and Doxorubicin
Number of subjects: 552
Study: 17339482

Group type: EXPERIMENTAL
Intervention: FH purified from sera of AMD patients homozygous for the FH(402H) variant
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Recombinant fragment of FH (short consensus repeat 5-7) containing the FH(402H) variant
Number of subjects: 2

Group type: COMPARATOR
Intervention: FH derived from unaffected controls homozygous for the FH(402Y) variant
Number of subjects: 2
Study: 15129404

Group type: COMPARATOR
Intervention: RBS
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PBS+RBS
Number of subjects: 22
Study: 11824175

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of porcine secretin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9510221

Group type: EXPERIMENTAL
Intervention: 15-session experimental group intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: 2-session control intervention
Number of subjects: 97
Study: 7992097

Group type: EXPERIMENTAL
Intervention: recombinant interferon-alpha 2a (rIFN-alpha 2a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard hydroxyurea chemotherapy
Number of subjects: 0
Study: 2662999

Group type: EXPERIMENTAL
Intervention: Exogenous natural surfactant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment at birth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified bovine surfactant
Number of subjects: 0
Study: 5494682

Group type: EXPERIMENTAL
Intervention: Tolazoline hydrochloride
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30193253

Group type: EXPERIMENTAL
Intervention: mHealth-supported n-of-1 trial
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 215
Study: 28032168

Group type: EXPERIMENTAL
Intervention: HA IDF plus (with Lidocaine)
Number of subjects: 62

Group type: COMPARATOR
Intervention: HA IDF (Without Lidocaine)
Number of subjects: 62
Study: 26693746

Group type: EXPERIMENTAL
Intervention: Test rice II (cooked white rice cooled for 24 hours at 4°C then reheated)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control rice (freshly cooked white rice)
Number of subjects: 15
Study: 23060621

Group type: EXPERIMENTAL
Intervention: Glaucoma medications (various types including prostaglandins, β blockers, and carbonic anhydrase inhibitors)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glaucoma medications (various types)
Number of subjects: 50
Study: 21510905

Group type: EXPERIMENTAL
Intervention: Weekly oral supplement containing vitamin A (7000 ug retinol equivalents)
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Weekly oral supplement containing beta-carotene (42 mg, or 7000 ug retinol equivalents)
Number of subjects: 60000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60000